doi: 10.3389/frph.2022.822257 Received 25 November 2021 Accepted 17 January 2022 Published 22 February 2022 Volume 4 - 2022 Edited by Roland Eghoghosoa Akhigbe, Ladoke Akintola University of Technology, Nigeria Reviewed by Giulia Collodel, University of Siena, Italy
10.1007/s00415-018-9144-9 149
This is the mechanistic reason researchers study it separately from native IGF-1: with less protein-binding interference, the analog remains bioavailable roughly 3x longer, giving it an extended half-life of approximately 2030 hours compared to native IGF-1s 1215 hours
The high purity of Polaris Peptidess Epithalon 10mg ensures that observed results are due to the peptide itself rather than impurities, allowing for clearer data interpretation
Another peptide therapy currently in research stages is Epitalon, a synthetic peptide linked in early research to telomere activity and longevity